Former RayzeBio CEO quickly returns with new biotech; Amgen’s global research leader steps down

Ken Song is back in busi­ness.

He left Rayze­Bio in Feb­ru­ary af­ter lead­ing the ra­dio­phar­ma­ceu­ti­cals start­up from Se­ries A to IPO in three years, and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.